Potential Mortality Reduction with Optimal Usage of Sacubitril/Valsartan Therapy for the Treatment of Heart Failure in Costa Rica
PARADIGM-HF, a phase III trial conducted in patients with heart failure and reduced ejection fraction (HFrEF), showed that sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor, provided incremental cardiovascular and overall survival benefit compared to enalapril. This analysis aimed to quantify the number of potential all-cause deaths that could be avoided with optimal usage of sacubitril/valsartan for the treatment of HFrEF in Costa Rica.
Source: Value in Health - Category: International Medicine & Public Health Authors: M Barbeau, F Bonilla, A Calvo, C Amaya, A MacPherson Source Type: research
More News: Cardiology | Cardiovascular | Costa Rica Health | Diovan | Enalapril | Heart | Heart Failure